Lai-Ming Kathleen Pak

1 month ago | onlinelibrary.wiley.com | Amanda Cox |Leon A Bach |Lai-Ming Kathleen Pak

References 1, , , , , et al. Experience with denosumab (XGEVA(R)) for prevention of skeletal-related events in the 10 years after approval. J Bone Oncol 2022; 33: 100416. 2, , , , , et al. Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management. Bone 2022; 154: 116202. 3, , . Prevalence of denosumab-induced hypocalcemia: a retrospective observational study of patients routinely monitored with ionized calcium post-injection.